Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › ethambutol

ethambutol

4 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of ethambutol

12 trials tracked of ethambutol: 5 in phase 3 or 4 and 2 with published results. The most-cited published study has 402 citations.

12Trials tracked
5Phase 3 & 4
0Recruiting
2With published results
Phase distribution
Phase 4 1 Phase 3 4 Phase 2 4 Other / NA 3
  1. Phase 3 The Evaluation of a Standard Treatment Regimen of Anti-tuberculosis Drugs for Patients With MDR-TB Completed · 402 cited
  2. Phase 3 Validation of Patient Reported Outcome Measures in Participants With Nontuberculous Mycobacterial Lung Infection Caused by Mycobacterium Avium Complex Completed · 2 cited
  3. Phase 4 Effect of Weight and/or Obesity on Ethambutol Drug Concentrations Completed
  4. Phase 3 A Study of Bedaquiline Administered as Part of a Treatment Regimen With Clarithromycin and Ethambutol in Adult Patients With Treatment-refractory Mycobacterium Avium Complex-lung Disease (MAC-LD) Completed
  5. Phase 3 Tuberculosis Treatment Shortening Trial Completed
  6. Phase 2 Evaluation of SQ109, High-dose Rifampicin, and Moxifloxacin in Adults With Smear-positive Pulmonary TB in a MAMS Design Completed
Show 6 more trials
  1. Phase 2 Essentiality of INH in TB Therapy Completed
  2. Phase 2 Phase II Investigation of Antimycobacterial Therapy on Progressive, Pulmonary Sarcoidosis Completed
  3. Phase 2 Assessing PA-824 for Tuberculosis (the APT Trial) Completed
  4. N/A Improving Treatment of Nontuberculous Mycobacterial Infection in Cystic Fibrosis Completed
  5. N/A Fermented Soybean Supplementation Among Active Pulmonary Tuberculosis Patients With Standard Therapy in Indonesia Completed
  6. N/A Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy Completed

Showing the 12 most-cited and recently-updated of 12 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Immediate antituberculosis therapy did not reduce mortality in HIV-related sepsis overall
Infectious Disease RCT
Immediate antituberculosis therapy did not reduce mortality in HIV-related sepsis overall Immediate TB treatment helps only those with confirmed infection in HIV sepsis
This trial investigated whether starting antituberculosis treatment immediately or using high doses improved survival in adults with HIV-rel…
In HIV sepsis, starting TB drugs immediately did not lower death rates overall, but helped only patients later confirmed to have TB.
Jun 1, 2026
Ethambutol optic neuropathy incidence 1.54 percent with renal impairment and hypertension as key risk factors
Ophthalmology Meta-analysis
Ethambutol optic neuropathy incidence 1.54 percent with renal impairment and hypertension as key risk factors Kidney disease and high blood pressure raise risk of vision loss from TB drug
This systematic review and meta-analysis synthesized evidence on ethambutol optic neuropathy and tuberculous meningitis complications. The p…
A massive review of over 260,000 patients found that kidney problems and high blood pressure make vision loss from the TB drug ethambutol mu…
Frontiers May 29, 2026
Systematic review of Mycobacterium riyadhense infection in 69 cases shows common presentations and drug susceptibility patterns
Infectious Disease Meta-analysis
Systematic review of Mycobacterium riyadhense infection in 69 cases shows common presentations and drug susceptibility patterns A rare infection hits lungs and bones: what doctors need to know about treating Mycobacterium riyadhense
A systematic review and meta-analysis of 69 immunocompetent and immunocompromised patients with Mycobacterium riyadhense infection found pne…
A rare lung and bone infection called Mycobacterium riyadhense often resists standard drugs, leaving doctors without agreed-upon treatment p…
Frontiers Apr 14, 2026
ALIS plus macrolide regimen improves culture conversion in noncavitary MAC lung disease
Infectious Disease RCT
ALIS plus macrolide regimen improves culture conversion in noncavitary MAC lung disease An Inhaled Antibiotic Shifts the Odds in a Stealthy Lung Infection
In a 99-patient RCT of adults with noncavitary MAC lung disease, adding 6 months of amikacin liposome inhalation suspension (ALIS) to a macr…
Adding a nebulized antibiotic to standard pills helped more newly diagnosed MAC lung patients clear the bug sooner, with no new safety surpr…
Apr 13, 2026